These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18024973)

  • 1. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment.
    Deforche K; Camacho R; Van Laethem K; Lemey P; Rambaut A; Moreau Y; Vandamme AM
    Bioinformatics; 2008 Jan; 24(1):34-41. PubMed ID: 18024973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model of directional selection applied to the evolution of drug resistance in HIV-1.
    Seoighe C; Ketwaroo F; Pillay V; Scheffler K; Wood N; Duffet R; Zvelebil M; Martinson N; McIntyre J; Morris L; Hide W
    Mol Biol Evol; 2007 Apr; 24(4):1025-31. PubMed ID: 17272680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.
    Sangeda RZ; Theys K; Beheydt G; Rhee SY; Deforche K; Vercauteren J; Libin P; Imbrechts S; Grossman Z; Camacho RJ; Van Laethem K; Pironti A; Zazzi M; Sönnerborg A; Incardona F; De Luca A; Torti C; Ruiz L; Van de Vijver DA; Shafer RW; Bruzzone B; Van Wijngaerden E; Vandamme AM;
    Infect Genet Evol; 2013 Oct; 19():349-60. PubMed ID: 23523594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.
    Beerenwinkel N; Däumer M; Sing T; Rahnenfuhrer J; Lengauer T; Selbig J; Hoffmann D; Kaiser R
    J Infect Dis; 2005 Jun; 191(11):1953-60. PubMed ID: 15871130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.
    Healy B; De Gruttola V; Pagano M
    Biometrics; 2007 Sep; 63(3):742-50. PubMed ID: 17403101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug induced superinfection in HIV and the evolution of drug resistance.
    Leontiev VV; Maury WJ; Hadany L
    Infect Genet Evol; 2008 Jan; 8(1):40-50. PubMed ID: 18024234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein evolution in viral quasispecies under selective pressure: a thermodynamic and phylogenetic analysis.
    Briones C; Bastolla U
    Gene; 2005 Mar; 347(2):237-46. PubMed ID: 15725390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance.
    Deforche K; Silander T; Camacho R; Grossman Z; Soares MA; Van Laethem K; Kantor R; Moreau Y; Vandamme AM;
    Bioinformatics; 2006 Dec; 22(24):2975-9. PubMed ID: 17021157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.
    Theys K; Deforche K; Beheydt G; Moreau Y; van Laethem K; Lemey P; Camacho RJ; Rhee SY; Shafer RW; Van Wijngaerden E; Vandamme AM
    BMC Bioinformatics; 2010 Aug; 11():409. PubMed ID: 20682040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombination in HIV and the evolution of drug resistance: for better or for worse?
    Bretscher MT; Althaus CL; Müller V; Bonhoeffer S
    Bioessays; 2004 Feb; 26(2):180-8. PubMed ID: 14745836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of HIV-1 in a patient population failing multiple-drug therapy.
    Hong S; Cao J; Tu YT
    Microbiol Immunol; 2009 Sep; 53(9):535-9. PubMed ID: 19703248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution on distributive lattices.
    Beerenwinkel N; Eriksson N; Sturmfels B
    J Theor Biol; 2006 Sep; 242(2):409-20. PubMed ID: 16650439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.